Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.67 |
| ▸ | STAT3 | P40763 | 5/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29880821 | 0.95 | CRBN (0.71) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL23302448 | 0.92 | CRBN (0.65) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL17536583 | 0.92 | CRBN (0.65) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL21259481 | 0.92 | CRBN (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL26813160 | 0.92 | STAT3 (0.64) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL23884342 | 0.92 | CRBN (0.64) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL24744631 | 0.92 | STAT3 (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL21996933 | 0.92 | CRBN (0.64) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL26853448 | 0.92 | STAT3 (0.64) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL24678269 | 0.92 | STAT3 (0.64) | CRBNDDB1STAT3CA2DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | CRBN 1/4885DDB1 360/4885STAT3 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.